Latest Anz News

Australia and New Zealand Banking Group Limited (ASX:AN3) reported a 27% increase in 2026 cash profit to $7.542 billion, helped by substantial cost reductions and stronger fee and trading income. The annual report also flags rising credit impairment, a softer housing market and unfinished regulatory remediation work.

ANZ Group Holdings reported a 31% rise in FY26 cash profit to A$7.591 billion, helped by sharp cost reductions and stronger Australian banking performance. The 83-cent final dividend was maintained, but rising impairments, weaker New Zealand earnings and heavier capital demands leave the next phase of the turnaround less straightforward.

Monvia delivered FY26 adjusted revenue and EBITDA slightly ahead of its IPO forecasts, while ARR climbed 21% to A$14 million. The ASX-listed insurance software provider now has a much larger pipeline, but expects FY27 total revenue to remain flat as professional services revenue eases.

City Chic says reduced discounting is lifting margins and store sales, putting the retailer on track for positive first-half EBIT and no drawn debt by the end of January. The improvement comes with revenue still under pressure, particularly in the USA and online channels, leaving the Black Friday and Christmas period decisive.

Reece delivered 4.3% sales growth in the first quarter of FY27, powered by a 12.8% increase across Australia and New Zealand. The US remained subdued, while management flagged a cautious view of the second half.

Knosys has moved its Libero library platform into active US commercialisation, identifying near-term sales opportunities while preparing for its first customer engagements. The push comes as ARR slips to A$8.7 million and a timing-affected quarter leaves the company with 2.03 quarters of estimated funding.

Adheris Health delivered a stronger first quarter on revenue, margins and its CY27 sales pipeline, but ended September with US$3.5 million in cash after a US$3.1 million operating outflow. The company also disclosed the impending loss of a major pharmacy partner and a US$2.3 million-plus legal claim.

Vita Resources is positioning itself as a small, focused Australian and New Zealand gold explorer, with Ninnis in Western Australia and a new Otago pipeline forming the centrepiece. The company says New Zealand exploration is expected to begin in 2027, while its early-stage projects remain dependent on exploration success, funding and approvals.

Pureprofile has started FY27 with record quarterly revenue of $18.3 million and EBITDA of $2.4 million, while Platform revenue more than doubled. The ASX-listed data and insights company maintained its revenue guidance and lifted its EBITDA margin outlook to 11% to 12%.

Ora Banda Mining (ASX:OBM) kept its FY27 guidance intact despite weather disruption and an extended mill shutdown lifting quarterly AISC to A$4,214 an ounce. The company is spending heavily to build its next production phase, with the new 3.0 Mtpa plant on schedule and Waihi Underground starting ahead of plan.

Recce Pharmaceuticals has granted Arrotex exclusive rights to commercialise its investigational RECCE 327 topical gel in Australia and New Zealand. The agreement offers a potential profit-share stream, but no upfront payments, sales forecast or approval have been disclosed.

Nick Scali expects first-half FY27 underlying net profit of $28 million to $32 million after a sharp slowdown in Australia and New Zealand. The UK business is growing strongly, but ANZ revenue is forecast to fall 11% to 14% and the company has booked almost $1 million in cyber incident costs.